![]() ![]() " Part of that was driven by some instruments that we had shipped out, but had not been able to fully install and get up and running due to COVID restrictions," he said. McAnear also noted that Q2 was "a really strong quarter" for the Chromium Connect instrument. "So definitely there is some amount of baked-in demand that's coming, but I'm not sure if I'd classified it like a huge tsunami kind of deal." Most of the interested customers are already in the 10x ecosystem, "but there's quite a few new customers as well that are coming up with interest in the platform, especially … more on the biotech side of the world," he said. "Our earliest, most forward-looking customers have been kind of asking for this kind of capability for a while," Saxonov said. 10x Genomics declined to provide sales expectations. How many the firm expects to sell this year is also unclear. "We just started talking to our customers with concrete specs and pricing," Saxonov said. We're pleased with the initial response and look forward to getting it in our customers' hands this quarter."ġ0x did not specify how much the Chromium X will cost, though in January, Saxonov said it would be around $100,000. "Chromium X was developed in response to the desire of many of our early customers to run ultra-high-throughput experiments. " This platform represents a huge advance for single-cell genomics, as it will allow our customers to supercharge the experiments, and they're getting as many as a million cells in a single run at a significantly lower cost per cell," Saxonov said. He also noted that the Chromium X was changing the economics of single-cell genomics in other ways. "That has been bearing some fruit getting into these areas." have made concerted efforts in the marketing organization to start reaching customers new to 10x," especially in neuroscience and infectious disease, said Serge Saxonov, 10x's CEO and cofounder. Many of the instruments went to customers new to 10x. "And what that means, as far as when the price is made $35,000 on a long-term basis, we'll have to measure that over time." McAnear added the company was "keeping a close eye" on pricing and how it affects demand. "So, I think some of that could be driven by the urgency of having a promotion that's expiring at the end of the quarter," he said. On the other, the promotion was originally set to end June 30, however, it has been made permanent. "And so that could drive a pretty large increase in installed base this year." On the one hand, "demand … is strong, especially at this price point," 10x CFO Justin McAnear said. Whether the price change could lead to an inflection point in adoption remains to be seen. Total instrument revenues tallied $16.9 million, a 131 percent increase from $7.3 million in the prior-year period.ġ0x Officials also discussed the other instruments in the Chromium lineup - the new Chromium X and automated Chromium Connect - as well as the financial implications of the company's settlement with Bio-Rad Laboratories over single-cell intellectual property. During a conference call following the release of the firm's second quarter financial results, company officials told investors that the sales promotion led to 100 instrument placements above what the company had otherwise expected. In April, in anticipation of launching its high-throughput Chromium X, which can process 1 million cells at a time, 10x dropped the price of the base model to $35,000, down from about $50,000. ![]() NEW YORK – 10x Genomics has slashed prices on its Chromium controller and the market has responded strongly, company officials said this week. This story has been updated to include a response from 10x Genomics. Advances in Clinical Genomics Profiling.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |